Description

Cilastatin CAS NO 82009-34-5 is a potent and specific renal dehydropeptidase-I (DHP-I) inhibitor. Its primary commercial value lies in its critical role as a co-administration agent with the carbapenem antibiotic imipenem, where it prevents renal metabolism and degradation of the antibiotic, thereby significantly enhancing its efficacy and therapeutic concentration in the body. This product is essential for pharmaceutical manufacturers and research institutions developing or producing combination antibiotic therapies, particularly in the fight against multi-drug resistant bacterial infections.

Application

• Pharmaceutical Active Ingredient (API): Primary use as a key component in combination antibiotic formulations, most notably with imipenem.
• Antibiotic Potentiator: Used in research and development to enhance the pharmacokinetic profile and urinary recovery of β-lactam antibiotics susceptible to renal degradation.
• Biochemical Research: Serves as a specific inhibitor for studying the enzyme dehydropeptidase-I (DHP-I) in renal and metabolic pathways.
• Veterinary Medicine: Potential application in veterinary antibiotic combinations for treating serious infections in animals.
• Reference Standard: Used in quality control laboratories as a high-purity standard for analytical testing and method validation.
• Intermediate Synthesis: Acts as a critical intermediate or starting material in the synthesis of more complex pharmaceutical compounds.

Basic Information

Product Name	Cilastatin
CAS No.	82009-34-5
Molecular Formula	C16H26N2O5S
Molecular Weight	358.46 g/mol
Synonyms	(Z)-7-[(2-Amino-2-carboxyethyl)thio]-2-[[(1S)-2,2-dimethylcyclopropanecarbonyl]amino]hept-2-enoic acid; MK-0791; Cilastatin Sodium; Cilastatinum; Cilastatina; Dehydropeptidase Inhibitor MK0791; (Z)-7-[(2-Amino-2-carboxyethyl)thio]-2-(((S)-2,2-dimethylcyclopropyl)carbonyl)aminohept-2-enoic acid
EINECS	Contact for details

Quality Control

Our Cilastatin is manufactured under strict quality management systems. Each batch undergoes rigorous analytical testing to ensure it meets high-purity standards suitable for pharmaceutical applications. We provide comprehensive Certificates of Analysis (COA) that detail purity, identity, and impurity profiles, with testing performed via validated methods such as HPLC, IR, and titration. Specifications can be aligned with pharmaceutical grade requirements, including potential compliance with ICH guidelines for impurities.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (typically 15-25°C). The product is hygroscopic (moisture-sensitive) and should be handled in a low-humidity environment to prevent degradation. For long-term stability, consider storage under an inert atmosphere.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	98.0% - 102.0% (on anhydrous basis)
Water Content (KF)	≤ 1.0%
Residue on Ignition	≤ 0.1%
Heavy Metals	≤ 20 ppm
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single impurity ≤ 0.5%
Specific Rotation	Contact for details

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.